(5R)-5-ethyl-5-methyl-3-[2-({4-methyl-3-[(trifluoromethyl)oxy]phenyl}oxy)-5-pyrimidinyl]-2,4-imidazolidinedione | 1311137-41-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (5R)-5-ethyl-5-methyl-3-[2-({4-methyl-3-[(trifluoromethyl)oxy]phenyl}oxy)-5-pyrimidinyl]-2,4-imidazolidinedione
• 英文别名: (5R)-5-ethyl-5-methyl-3-[2-[4-methyl-3-(trifluoromethoxy)phenoxy]pyrimidin-5-yl]imidazolidine-2,4-dione
• CAS: 1311137-41-3
• 化学式: C₁₈H₁₇F₃N₄O₄
• 分子量: 410.353
• InChiKey: DZJBKKVCXVSFHQ-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.6
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] IMIDAZOLIDINEDIONE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLIDINEDIONE
  申请人：GLAXO GROUP LTD

  公开号：WO2011069951A1

  公开（公告）日：2011-06-16

  The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

  这项发明提供了化合物(Ia)及其药学上可接受的盐。该发明还提供了将这些化合物或盐用作Kv3.1和/或Kv3.2的调节剂，以及在需要Kv3.1和/或Kv3.2调节剂的疾病或紊乱的治疗中的用途，如抑郁症和情绪障碍、听觉障碍、精神分裂症、物质滥用障碍、睡眠障碍或癫痫病。
• [EN] TRIAZOLES AS KV3 INHIBITORS<br/>[FR] TRIAZOLES EN TANT QU'INHIBITEURS DE KV3
  申请人：AUTIFONY THERAPEUTICS LTD

  公开号：WO2013175215A1

  公开（公告）日：2013-11-28

  Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

  式(I)的化合物可用于调节Kv3.1、Kv3.2和Kv3.3通道，并在相关疾病的治疗或预防中具有用途。
• IMIDAZOLIDINEDIONE DERIVATIVES
  申请人：Alvaro Giuseppe

  公开号：US20120289526A1

  公开（公告）日：2012-11-15

  The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy.

  本发明提供了公式（Ia）的化合物及其药学上可接受的盐。本发明还提供了将该化合物或盐用作Kv3.1和/或Kv3.2调节剂以及治疗需要Kv3.1和/或Kv3.2调节剂的疾病或障碍，例如抑郁和情绪障碍，听力障碍，精神分裂症，物质滥用障碍，睡眠障碍或癫痫。
• TRIAZOLES AS KV3 INHIBITORS
  申请人：AUTIFONY THERAPEUTICS LIMITED

  公开号：US20150111910A1

  公开（公告）日：2015-04-23

  Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

  公式（I）的化合物可用于调节Kv3.1，Kv.3.2和Kv3.3通道，并在相关疾病的治疗或预防中具有用途。
• Imidazolidinedione derivatives
  申请人：AUTIFONY THERAPEUTICS LIMITED

  公开号：US10058551B2

  公开（公告）日：2018-08-28

  The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

  本发明提供了式 (Ia) 的化合物及其药学上可接受的盐。本发明还提供了这些化合物或盐作为 Kv3.1 和/或 Kv3.2 调节剂的用途，以及在治疗需要 Kv3.1 和/或 Kv3.2 调节剂的疾病或紊乱中的用途，例如抑郁症和情绪紊乱、听力紊乱、精神分裂症、药物滥用紊乱、睡眠紊乱或癫痫。